Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 194

1.

Anaphylactoid reaction to muromonab-CD3 in a pediatric renal transplant recipient.

Berkowitz RJ, Possidente CJ, McPherson BR, Guillot A, Braun SV, Reese JC.

Pharmacotherapy. 2000 Jan;20(1):100-4.

PMID:
10641983
[PubMed - indexed for MEDLINE]
2.

OKT3 (muromonab-CD3) associated hepatitis in a kidney transplant recipient.

Go MR, Bumgardner GL.

Transplantation. 2002 Jun 27;73(12):1957-9.

PMID:
12131696
[PubMed - indexed for MEDLINE]
3.

Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection.

Georgitis JW, Browning MC, Steiner D, Lorentz WB.

Ann Allergy. 1991 Apr;66(4):343-7.

PMID:
1901692
[PubMed - indexed for MEDLINE]
4.

Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3).

Hartnick CJ, Cohen AF, Smith RV.

Ann Otol Rhinol Laryngol. 1997 Aug;106(8):640-2.

PMID:
9270425
[PubMed - indexed for MEDLINE]
5.

Visual loss complicating OKT3 monoclonal antibody therapy in a renal transplant recipient.

Jin DC, Kim SY, Lee JM, Koo WS, Choi EJ, Yoon YS, Bang BK.

Nephrol Dial Transplant. 1995 Nov;10(11):2144-6. No abstract available.

PMID:
8643188
[PubMed - indexed for MEDLINE]
6.

Reversible sensorineural hearing loss following administration of muromonab-CD3 (OKT3) for cadaveric renal transplant immunosuppression.

Hartnick CJ, Smith RV, Tellis V, Greenstein S, Ruben RJ.

Ann Otol Rhinol Laryngol. 2000 Jan;109(1):45-7.

PMID:
10651411
[PubMed - indexed for MEDLINE]
7.

Prevention of the OKT3 first-dose syndrome by reduced initial dose followed by adjusted doses based on CD3 T-lymphocyte counts in pediatric renal graft recipients.

Piatosa B, Grenda R, Prokurat S.

Transplant Proc. 1996 Dec;28(6):3466-7. No abstract available.

PMID:
8962349
[PubMed - indexed for MEDLINE]
8.

Anaphylactic hypersensitivity reaction after repeat OKT3 treatment.

Werier J, Cheung AH, Matas AJ.

Lancet. 1991 Jun 1;337(8753):1351. No abstract available.

PMID:
1674327
[PubMed - indexed for MEDLINE]
9.

Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect.

Heifets M, Saeed MI, Parikh MH, Sierka D, Kumar MS.

Drugs Aging. 2004;21(11):747-56.

PMID:
15323580
[PubMed - indexed for MEDLINE]
10.

Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review.

Sgro C.

Toxicology. 1995 Dec 20;105(1):23-9. Review.

PMID:
8638282
[PubMed - indexed for MEDLINE]
11.

Muromonab-CD3-induced neurotoxicity: report of two siblings, one of whom had subsequent cyclosporin-induced neurotoxicity.

Thaisetthawatkul P, Weinstock A, Kerr SL, Cohen ME.

J Child Neurol. 2001 Nov;16(11):825-31.

PMID:
11732768
[PubMed - indexed for MEDLINE]
12.

Effect of oral pentoxyfylline on the OKT3-induced cytokine-release syndrome among renal allograft recipients.

Vasquez EM, Pollak R.

Clin Transplant. 1996 Jun;10(3):294-7.

PMID:
8826669
[PubMed - indexed for MEDLINE]
13.

Generalized seizures associated with the use of muromonab-CD3 in two patients after kidney transplantation.

Seifeldin RA, Lawrence KR, Rahamtulla AF, Monaco AP.

Ann Pharmacother. 1997 May;31(5):586-9.

PMID:
9161654
[PubMed - indexed for MEDLINE]
14.

Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation.

Benekli M, Hahn T, Williams BT, Cooper M, Roy HN, Wallace P, Stewart C, Bambach B, McCarthy PL Jr.

Bone Marrow Transplant. 2006 Sep;38(5):365-70. Epub 2006 Jul 24.

PMID:
16862164
[PubMed - indexed for MEDLINE]
15.

The OKT3 Antibody Response Study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation.

Kimball JA, Norman DJ, Shield CF, Schroeder TJ, Lisi P, Garovoy M, O'Connell JB, Stuart F, McDiarmid SV, Wall W.

Transpl Immunol. 1995 Sep;3(3):212-21.

PMID:
8581409
[PubMed - indexed for MEDLINE]
16.

Detection of IGA anti-OKT3 antibodies in OKT3-treated transplant recipients.

McIntyre JA, Kincade M, Higgins NG.

Transplantation. 1996 May 27;61(10):1465-9.

PMID:
8633372
[PubMed - indexed for MEDLINE]
17.

Development of anti-OKT3 antibodies after OKT3 treatment.

Jensen PB, Birkeland SA, Rohrp N, Elbirk A, Jørgensen KA.

Scand J Urol Nephrol. 1996 Jun;30(3):227-30.

PMID:
8837256
[PubMed - indexed for MEDLINE]
18.

Modulation of peripheral blood T-lymphocytes in kidney transplant recipients treated with low dose OKT3 therapy.

Galante NZ, Câmara NO, Kallás EG, Salomão R, Pacheco-Silva A.

Immunol Lett. 2004 Jan 30;91(1):75-7.

PMID:
14757373
[PubMed - indexed for MEDLINE]
19.

Acute thrombosis of the renal transplant artery after a single dose of OKT3.

Shankar R, Bastani B, Salinas-Madrigal L, Sudarshan B.

Am J Nephrol. 2001 Mar-Apr;21(2):141-4.

PMID:
11359022
[PubMed - indexed for MEDLINE]
20.

Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly sensitized renal transplant recipients.

Vela C, Cristol JP, Chong G, Okamba A, Lorho R, Mion C, Mourad G.

Transpl Int. 1994;7 Suppl 1:S259-62.

PMID:
11271219
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk